Details
Stereochemistry | ACHIRAL |
Molecular Formula | C29H27F2N7O5S |
Molecular Weight | 623.63 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=CC=C(OC)N=N5
InChI
InChIKey=AOMXMOCNKJTRQP-UHFFFAOYSA-N
InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)
Molecular Formula | C29H27F2N7O5S |
Molecular Weight | 623.63 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Relugolix (TAK-385) is an orally active nonpeptide gonadotropin-releasing hormone (GnRH) that binds to human GnRH receptors with subnanomolar affinity. Relugolix was demonstrated to act as a classic competitive antagonist of GnRH binding, but the exact molecular mechanism of that antagonism remains unknown. This drug is being developed as a treatment for various sex hormone related disorders. Clinical trials have been conducted to study safety and efficacy of relugolix as a treatment in endometriosis, uterine fibroids (noncancerous growths of the uterus), and prostate cancer. Two phase III trials evaluating the efficacy of Relugolix in patients with uterine fibroids were completed in 2019. No serious adverse events were reported.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1855 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21657270 |
0.08 nM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. | 2011 Jul 28 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 06:45:13 UTC 2022
by
admin
on
Sat Dec 17 06:45:13 UTC 2022
|
Record UNII |
P76B05O5V6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English Albanian | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C63347
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P76B05O5V6
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
C114498
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
9628
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
CHEMBL1800159
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
CD-128
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
RELUGOLIX
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
10348973
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
DTXSID40224167
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
DB11853
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
P76B05O5V6
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
737789-87-6
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY | |||
|
2472778
Created by
admin on Sat Dec 17 06:45:13 UTC 2022 , Edited by admin on Sat Dec 17 06:45:13 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INDUCER | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
|
||
|
BINDER->LIGAND |
Plasma protein binding of relugolix is 68 to 71%, primarily to albumin and to a lesser extent to ?1-acid glycoprotein.
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Co-administration with rifampin (P-gp and strong CYP3A inducer) decreased the AUC and Cmax of relugolix by 55% and 23%, respectively.
MAJOR
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE |
Relugolix is a substrate for intestinal P-gp.Co-administration with rifampin (P-gp and strong CYP3A inducer) decreased the AUC and Cmax of relugolix by 55% and 23%, respectively.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
terminal elimination half-life | PHARMACOKINETIC |
|
|
|||
blood-to-plasma ratio | PHARMACOKINETIC |
|
|
|||
effective half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||